Institute of Medicinal Plants ACECR

Tehrān, Iran

Institute of Medicinal Plants ACECR

Tehrān, Iran
SEARCH FILTERS
Time filter
Source Type

Asadi F.,Tehran University of Medical Sciences | Razmi A.,Institute of Medicinal Plants ACECR | Dehpour A.R.,Tehran University of Medical Sciences | Shafiei M.,Tehran University of Medical Sciences
Journal of Pharmacy and Pharmacology | Year: 2016

Objectives Cardiomyocyte hypertrophy is an important structural feature of diabetic cardiomyopathy. Calcineurin/nuclear factor of activated T-cell (NFAT) pathway plays a central role in the pathogenesis of cardiac hypertrophy. The purpose of this study was to investigate the effects of tropisetron, a novel calcineurin inhibitor, on high glucose (HG)-induced cardiomyocyte hypertrophy and its underlying mechanism. Methods H9c2 myocardial cells were treated with tropisetron or cyclosporine A 1 h before exposure to HG for 48 h. Key findings Exposure to HG resulted in enhanced cell size, protein content and atrial natriuretic peptide (ANP) protein expression. HG significantly increased Ca2+ level, calcineurin expression and nuclear translocation of NFATc4. Both tropisetron and cyclosporine A markedly prevented the hypertrophic characteristic features, calcineurin overexpression and nuclear localization of NFATc4 while intracellular Ca2+ was not affected. Conclusion Our results showed that tropisetron may have protective effects against HG-induced cardiomyocyte hypertrophy. The mechanism responsible for this beneficial effect seems to be, at least in part, blockade of calcineurin/NFAT signalling pathway. © 2016 Royal Pharmaceutical Society.


Rezaei V.,Shiraz University of Medical Sciences | Mohammadi M.-R.,Tehran University of Medical Sciences | Ghanizadeh A.,Shiraz University of Medical Sciences | Sahraian A.,Shiraz University of Medical Sciences | And 3 more authors.
Progress in Neuro-Psychopharmacology and Biological Psychiatry | Year: 2010

Background: Autism is a complex neurodevelopmental disorder that forms part of a spectrum of related disorders referred to as Autism Spectrum Disorders. The present study assessed the effects of topiramate plus risperidone in the treatment of autistic disorder. Method: Forty children between the ages of 4 and 12. years with a DSM IV clinical diagnosis of autism who were outpatients from a specialty clinic for children were recruited. The children presented with a chief complaint of severely disruptive symptoms related to autistic disorder. Patients were randomly allocated to topiramate. +. risperidone (Group A) or placebo. +. risperidone (Group B) for an 8-week, double-blind, placebo-controlled study. The dose of risperidone was titrated up to 2. mg/day for children between 10 and 40. kg and 3. mg/day for children weighting above 40. kg. The dose of topiramate was titrated up to 200. mg/day depending on weight (100. mg/day for < 30. kg and 200. mg/day for > 30. kg). Patients were assessed at baseline and after 2, 4, 6 and 8. weeks after starting medication. Measure of outcome was the Aberrant Behavior Checklist-Community (ABC-C) Rating Scale. Results: Difference between the two protocols was significant as the group that received topiramate had a greater reduction in ABC-C subscale scores for irritability, stereotypic behavior and hyperactivity/noncompliance. Conclusion: The results suggest that the combination of topiramate with risperidone may be superior to risperidone monotherapy for children with autistic disorder. However the results need to be further confirmed by a larger randomized controlled trial. © 2010 Elsevier Inc.


Radjabian T.,Shahed University | Fallah Huseini H.,Institute of Medicinal Plants ACECR
Iranian Journal of Pharmacology and Therapeutics | Year: 2010

The object of this study is to evaluate the influence of silymarins from cultivated and wild Silybum marianum L. plants with different content of flavonolignans, especially silibinin on serum lipids levels and on the experimental atherosclerosis development in rabbits fed on high cholesterol-diet (HCD). Forty eight male six-months-old white New Zealand rabbits (1.8-2 kg) were randomly assigned into six equal groups: positive control group - fed on HCD, negative control group- fed on standard laboratory diet and four groups fed on HCD with two different doses (100 and 200 mg/kg/day) of silymarins from cultivated and wild plants. Silymarin extracts were administered via the oral route, once daily for 2 months. Feeding of rabbits on HCD supplemented with both silymarins from cultivated and wild plants at the dose of 200 mg/kg/d caused a significant decrease in levels of total cholesterol, LDL-C and triacylglycerols. On the other hand, administration of silymarin from cultivated plants at the dose of 200 mg/kg/d in the diet enhanced significantly HDL-C serum content of rabbits. Both silymarins, at the dose of 200 mg/kg/d showed a significant inhibition of atherosclerotic plaque formation. Although a clear dose-dependent relationship was observed at the applied doses, but the pharmacological effects of silymarin from wild plants with lower content of silibinin, at the dose of 100 mg/kg/d were compared to those of silymarin of cultivated ones. Our results confirmed the anti-hyperlipidemic and anti-atherosclerotic effects of silymarins from both cultivated and wild milk thistle plants. In addition, the results allowed us to suggest that other constituents rather than silybinin may be responsible for therapeutic effects of silymarin. © 2010 by Razi Institute for Drug Research (RIDR).


Akhondzadeh S.,Tehran University of Medical Sciences | Ghayyoumi R.,Tehran University of Medical Sciences | Rezaei F.,Kurdistan University of Medical Sciences | Salehi B.,Arak University of Medical Sciences | And 7 more authors.
Psychopharmacology | Year: 2011

Rational: It has been suggested that phosphodiesterase 5 inhibitors such as sildenafil may be effective in the treatment of negative symptoms of schizophrenia. Objective: This study was designed to investigate the effect of sildenafil added to risperidone as augmentation therapy in patients with chronic schizophrenia and prominent negative symptoms in a double-blind and randomized clinical trial. Methods: Eligible participants in the study were 40 patients with chronic schizophrenia with ages ranging from 18 to 45 years. All patients were inpatients and were in the active phase of the illness and met DSM-IV-TR criteria for schizophrenia. Patients were allocated in a random fashion: 20 to risperidone (6 mg/day) plus sildenafil (75 mg/day) and 20 to risperidone (6 mg/day) plus placebo. The principal measure of outcome was Positive and Negative Syndrome Scale (PANSS). Results: Although both protocols significantly decreased the score of the positive, negative, and general psychopathological symptoms over the trial period, the combination of risperidone and sildenafil showed a significant superiority over risperidone alone in decreasing negative symptoms and PANSS total scores over the 8-week trial (between-subjects factor; F = 4.77, df = 1; P = 0.03; F = 5.91, df = 1, P = 0.02 respectively). Conclusion: Therapy with 75 mg/day of sildenafil was well tolerated, and no clinically important side effects were observed. The present study indicates sildenafil as a potential adjunctive treatment strategy for treatment of negative symptoms of schizophrenia. This trial is registered with the Iranian Clinical Trials Registry (IRCT1138901151556N11). © 2010 Springer-Verlag.


Abbasi S.-H.,Tehran University of Medical Sciences | Behpournia H.,Tehran University of Medical Sciences | Ghoreshi A.,Zanjan University of Medical Sciences | Salehi B.,Arak University of Medical Sciences | And 4 more authors.
Schizophrenia Research | Year: 2010

It has been reported that mirtazapine would be helpful for treating negative symptoms in schizophrenia. Nevertheless, the results are contradictory so far. This study was designed to investigate the effect of mirtazapine added to risperidone as augmentation therapy in patients with chronic schizophrenia and prominent negative symptoms in a double-blind and randomized clinical trial. Eligible participants in the study were 40 patients with chronic schizophrenia with ages ranging from 19 to 49 years. All patients were inpatients and were in the active phase of the illness, and met DSM-IV-TR criteria for schizophrenia. Patients were allocated in a random fashion 20 to risperidone 6 mg/day plus mirtazapine 30 mg/day and 20 to risperidone 6 mg/day plus placebo. The principal measure of the outcome was Positive and Negative Syndrome Scale (PANSS). The mirtazapine group had significantly greater improvement in the negative symptoms and PANSS total scores over the eight-week trial. Therapy with 30 mg/day of mirtazapine was well tolerated and no clinically important side effects were observed. The present study indicates mirtazapine as a potential combination treatment strategy for chronic schizophrenia particularly for negative symptoms. © 2009 Elsevier B.V. All rights reserved.


Hasanzadeh E.,Tehran University of Medical Sciences | Mohammadi M.-R.,Tehran University of Medical Sciences | Ghanizadeh A.,Shiraz University of Medical Sciences | Rezazadeh S.-A.,Institute of Medicinal Plants ACECR | And 3 more authors.
Child Psychiatry and Human Development | Year: 2012

Ginkgo biloba has been reported to affect the neurotransmitter system and to have antioxidant properties that could impact the pathogenesis of Autism Spectrum Disorder. Based on these studies, we decided to assess the effectiveness of Ginkgo biloba extract (Ginko T.D., Tolidaru, Iran) as an adjunctive agent to risperidone in the treatment of autism. Forty-seven outpatients with a DSM-IV-TR diagnosis of autism ages between 4 and 12 years were assigned to this double blinded clinical trial and were randomly divided into two groups. One group received risperidone plus Ginko T.D and the other received risperidone plus placebo. The dose of risperidone was 1-3 mg/day and the dose of Ginko T.D. was 80 mg/day for patients under 30 kg and 120 mg/day for patients above 30 kg. Patients were assessed using Aberrant Behavior Checklist-Community (ABC-C) rating scale and the side effect check list every 2 weeks until the endpoint. None of the 5 subscales of ABC-C rating scale showed significant differences between the two groups. Incidents of side effects were not significantly different between the two groups. Adding Ginkgo biloba to risperidone did not affect the treatment outcome of ADs. Nevertheless, further observations are needed to confirm this result. © Springer Science+Business Media, LLC 2012.


Saroukhani S.,Tehran University of Medical Sciences | Emami-Parsa M.,Tehran University of Medical Sciences | Modabbernia A.,Tehran University of Medical Sciences | Ashrafi M.,Tehran University of Medical Sciences | And 3 more authors.
Bipolar Disorders | Year: 2013

Objectives: The aim of the present study was to assess the effect of aspirin on lithium-related sexual dysfunction in men with stable bipolar affective disorder (BAD). Methods: In a randomized, double-blind, placebo-controlled study, 32 men with stable BAD who had been on lithium maintenance therapy randomly received aspirin (240 mg/day) or placebo for six weeks. The International Index for Erectile Function (IIEF) was used to assess sexual symptoms at baseline, Week 3, and Week 6. Depressive and mania symptoms and plasma lithium concentrations were assessed at baseline and Week 6. Side effects were assessed using a checklist. Results: Thirty patients (15/group) completed the study. Baseline and endpoint lithium concentrations and mania and depressive symptoms did not differ significantly between the two groups. Significant effects of time × treatment interaction were observed for total score [Greenhouse-Geisser: F(1.410,39.466) = 6.084, p = 0.010] and erectile function [Greenhouse-Geisser: F(1.629,45.602) = 7.250, p = 0.003]. By Week 6, patients in the aspirin group showed significantly greater improvement in the total (63.9% improvement from the baseline) and erectile function domain (85.4% improvement from the baseline) scores than the placebo group (14.4% and 19.7% improvement from the baseline, p-values = 0.002 and 0.001, respectively). By Week 6, 12 (80%) patients in the aspirin group and three (20%) patients in the placebo group met the criteria of minimal clinically important change [χ2(1) = 10.800, p = 0.001]. Other IIEF domains also showed significant improvement at the end of the trial. The frequency of side effects was similar between the two groups. Conclusion: Aspirin effectively improves lithium-related sexual dysfunction in men with stable BAD. © 2013 John Wiley & Sons A/S.


Mohammadi M.-R.,Tehran University of Medical Sciences | Kazemi M.-R.,Tehran University of Medical Sciences | Zia E.,Tehran University of Medical Sciences | Rezazadeh S.-A.,Institute of Medicinal Plants ACECR | And 2 more authors.
Human Psychopharmacology | Year: 2010

Objective The aim of the present study was to further evaluate, under double blind and controlled conditions, the efficacy of amantadine for attention-deficit/hyperactivity disorder (ADHD) in children and adolescents as compared to methylphenidate. Methods This was a 6-week randomized clinical trial. Forty patients (28 boys and 12 girls) with a DSM-IV-TR diagnosis of ADHD were the study population of this trial. All study subjects were randomly assigned to receive the treatment using capsule of amantadine at a dose of 100-150 mg/day depending on weight (100 mg/day for <30 kg and 150 mg/day for >30 kg) or methylphenidate at a dose of 20-30 mg/day for a 6-week double blind, randomized clinical trial. The principal measure of outcome was the Teacher and Parent Attention deficit/hyperactivity disorder Rating Scale-IV. Results No significant differences were observed between the two groups on the Parent and Teacher Rating Scale scores (df = 1; F = 0.02; p = 0.86 and df = 1; F = 0.01; p = 0.89, respectively). Side effects of decreased appetite and restlessness were observed more frequently in the methylphenidate group. Conclusion The results of this study indicate that amantadine significantly improved symptoms of ADHD and was well tolerated and it may be beneficial in the treatment of children with ADHD. Nevertheless, the present results do not constitute proof of efficacy. © 2010 John Wiley & Sons, Ltd.


Ghaleiha A.,Hamadan University of Medical Sciences | Entezari N.,Tehran University of Medical Sciences | Modabbernia A.,Tehran University of Medical Sciences | Najand B.,Tehran University of Medical Sciences | And 5 more authors.
Journal of Psychiatric Research | Year: 2013

There is a growing body of evidence for the efficacy of memantine augmentation in patients with obsessive-compulsive disorder (OCD). However, to date, no double-blind study has addressed this issue. The objective of the present randomized double-blind placebo-controlled study was to evaluate efficacy and tolerability of memantine add-on treatment in patients with moderate to severe OCD. Forty-two patients with the diagnosis of OCD based on DSM-IV-TR who had a Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score of ≥21 were randomly assigned to memantine (10 mg/day for the first week, and 20 mg/day for the rest of the trial) or placebo in addition to fluvoxamine for eight weeks. Patients were assessed using Y-BOCS every two weeks. Thirty-eight patients completed the study. Repeated measure ANOVA showed significant effect for time × treatment interaction in total scale [F (2.096, 75.470) = 5.280, P = 0.006] and obsession [F (2.340, 94.547) = 5.716, P = 0.002] and near significant effect for compulsion subscales [F (2.005, 79.179) = 2.841, P = 0.065]. By week eight, all patients in the memantine group and six (32%) patients in the placebo group [P value of Fisher's exact test <0.001] met the criteria for partial and complete response. At the end of the trial, 17 (89%) patients in the memantine group compared with six (32%) patients in the placebo group achieved remission (χ2(1) = 13.328, P < 0.001). Frequency of side-effects was not significantly different between the two groups. In summary, we showed that memantine add-on to fluvoxamine significantly improved short-term outcomes in patients with moderate to severe OCD. © 2012 Elsevier Ltd.


Ghaleiha A.,Hamadan University of Medical Sciences | Asadabadi M.,Tehran University of Medical Sciences | Mohammadi M.-R.,Tehran University of Medical Sciences | Shahei M.,Tehran University of Medical Sciences | And 4 more authors.
International Journal of Neuropsychopharmacology | Year: 2013

Autism is a neurodevelopmental disorder that causes significant impairment in socialization and communication. It is also associated with ritualistic and stereotypical behaviour. Recent studies propose both hyper-and hypoglutamatergic ideologies for autism. The objective of this study was to assess the effects of memantine plus risperidone in the treatment of children with autism. Children with autism were randomly allocated to risperidone plus memantine or placebo plus risperidone for a 10-wk, double-blind, placebo-controlled study. The dose of risperidone was titrated up to 3 mg/d and memantine was titrated to 20 mg/d. Children were assessed at baseline and after 2, 4, 6, 8 and 10 wk of starting medication protocol. The primary outcome measure was the irritability subscale of Aberrant Behavior Checklist-Community (ABC-C). Difference between the two treatment arms was significant as the group that received memantine had greater reduction in ABC-C subscale scores for irritability, stereotypic behaviour and hyperactivity. Eight side-effects were observed over the trial, out of the 25 side-effects that the checklist included. The difference between the two groups in the frequency of side-effects was not significant. The present study suggests that memantine may be a potential adjunctive treatment strategy for autism and it was generally well tolerated. This trial is registered with the Iranian Clinical Trials Registry (IRCT1138901151556N10; www.irct.ir) © 2012 CINP.

Loading Institute of Medicinal Plants ACECR collaborators
Loading Institute of Medicinal Plants ACECR collaborators